NeuroSoV is a privately held, pre-clinical stage biopharmaceutical company currently headquartered in Portugal with an established consortium of differentiated international partners. 

NeuroSoV is pioneering the research of disease-modifying treatments for devastating Neurological Disorders by leveraging the existing pathological mechanisms knowledge associated with these burdensome disorders of public health concern to develop innovative molecules with the potential to change the natural course of disease. Our proposed transformative approach relies on a multidisciplinary team aiming to boost Parkinson's Disease drug development to prevent disease progression. 

NeuroSoV's first lead candidate in development targets one of the main identified underlying Parkinson's Disease pathological mechanism with a differentiated reformulated technology with the promise to delay disease progression while enhancing patients quality of life bringing every single individual closer to their family and loved ones. 

We are focused on developing new small molecules which tackle the oxidative stress involved in PD, aiming to target NADPH oxidase 1 (NOX1), a known source of oxidative stress deleterious to dopaminergic neurons in PD, using an ionic liquid based NOX1 inhibitor (N1inh-IL).

NeuroSoV

Org chart

Teams

Offices